From breakthrough to manufacturing readiness: why ATMP industrialization becomes a patient safety issue

Immagine-Articolo-1_CAR-T_ABM3.0_Fedegari_2026_v3.0

In advanced therapies, the scientific breakthrough comes first. But it is not enough.

When a therapy depends on a patient’s own cells, manufacturing becomes part of the treatment itself. It is no longer a distant industrial phase. It becomes the boundary between a biological possibility and a therapy that can reach the patient with consistency, safety and time under control.

This is where ATMPs and CAR-T therapies expose a new industrial question. Not whether science can create the treatment. But whether manufacturing can make it accessible.

The future of advanced therapies will not be defined by discovery alone. It will be defined by the ability to make that discovery reproducible, scalable and compatible with regulated pharmaceutical production.

The challenge is not only to automate. It is to industrialize without losing control of the process.

Dollar_v2

THERAPY
COST

373,000 - 500,000 +

Per single infusion

Failure_v2 (1)

MANUFACTURING
FAILURE RATE

4% - 7%

Estimated range

Demand_v2

PATIENT ACCESS /
DEMAND

100,000 +

Batches estimated for the European market over the next decade

Delay_v3

DELIVERY /
TIME-TO-VEIN

14 - 28 days

Time that manual sterility testing adds to the entire process

Where advanced therapies meet their manufacturing limit

ATMPs are changing the therapeutic landscape. Their potential is no longer a theoretical promise, but the production model behind them still carries a structural weakness.

Biological science has moved faster than physical manufacturing. Cell therapy processes are still based on manual workflows, highly specialized operators, repeated handling steps and centralized production models.

This creates a gap between what the therapy can do and what the manufacturing system can reliably support.

That gap is becoming harder to ignore: the European market alone is expected to require more than 100,000 therapy batches over the next decade.

Polygon 5

Fragility is built into the manual model

Manual ATMP manufacturing can be controlled at limited scale. But as demand grows, its fragility becomes structural.

It begins with operator-dependent steps and repeated transfers, where consistency relies on human execution across a process that must remain tightly controlled.

→ It increases when fragile biological material has to be handled under strict conditions, often within workflows that depend on highly specialized workforces: the industrial-scale production could require up to 1,700 operators for a single facility.

→ It becomes visible in cost, with single infusions ranging from USD 373,000 to more than USD 500,000.

→ It becomes critical in time, when manual sterility testing can add 14 to 28 days to the process.

→ And it becomes non-negotiable in reliability, with manufacturing failure rates estimated between 4% and 7%.

In standard manufacturing, failure means lost efficiency. In autologous cell therapy, failure means a patient-specific therapy never reaches the patient it was made for.

This is why manual variability is not only an operational issue. It is a process responsibility.

Source: Journal of Cytotherapy

More capacity does not solve structural fragility

A fragile process cannot become robust by simply becoming larger. Adding operators, cleanroom space and manual repetitions may increase capacity, but it does not necessarily reduce variability. It can multiply the number of interactions that need to remain under control.

This is the limit of a production model that grows by adding manual complexity.

For advanced therapies to move beyond restricted access, manufacturing must change its logic. It must reduce dependency on repeated human intervention where that intervention can become a source of variability, contamination or delay.

The question is no longer how to reproduce an artisanal process at greater scale. The question is how to redesign the manufacturing model so that scale does not amplify fragility.

Illustrazione-4_ABM3.0-Ep.3-CAR-T_Fedegari_2026_v1.0

 

From robotic automation to aseptic architecture

The movement of cells through a robotic cluster is not only a mechanical sequence. Every transfer, every interface and every interaction with the environment can affect the integrity of the process. This is why automation must be framed within an aseptic manufacturing architecture.

Fedegari’s role enters at this level. In the collaboration with Multiply Labs, Fedegari contributes two critical pillars.

The first is the automated sterilization and decontamination module integrated with the robotic cluster. Its purpose is to close the contamination-risk loop around a process where biological material, equipment and environment must remain under control.

The second is the regulatory-compliant manufacturing of the robotic systems themselves. Fedegari supports the production of the systems according to pharmaceutical-grade and GMP expectations, helping transform the robotic cluster into an industrial asset ready for regulated manufacturing environments.

This is not a secondary layer. It is the condition that allows robotics to move from technological capability to pharmaceutical manufacturing readiness. The process comes first. The architecture must follow.

Illustrazione-Box_Trasparente_ABM3.0-Ep.3-CAR-T_Fedegari_2026_v2.0

 

Polygon 5

Why manufacturing readiness changes the outcome

The outcome of ATMP industrialization is not automation. It is access.

Published and project validation data indicate up to 74% reduction in manufacturing cost and up to 100x higher throughput per square foot compared with manual processes. They also indicate reduced operator exposure and contamination risk through closed robotic operation combined with automated sterilization and decontamination.

These figures are not only performance indicators. They describe what changes when the manufacturing model becomes less fragile.

Lower cost can reduce one of the strongest barriers to therapy availability. Higher throughput can make production more compatible with the expected demand for therapy batches.

Reduced exposure to manual intervention can support greater consistency and lower contamination risk. More controlled workflows can contribute to reducing the pressure on time-to-vein, one of the most critical constraints for patients waiting for treatment.

In this context, efficiency is not a separate business advantage. It becomes part of patient safety.

Toward decentralized and scalable production

Centralized megafactories have supported the first phase of industrial growth for cell therapies, but they also create distance between the patient and the production line. As demand increases, the next phase points toward more flexible, modular and decentralized models, including point-of-care manufacturing scenarios where production can move closer to hospitals and patients.

This transition cannot happen by reducing control. It can only happen if control is built into the manufacturing architecture.

Modularity, automation, sterilization, decontamination and GMP-compliant system manufacturing become part of the same industrial question: how to make advanced therapies producible in a way that is scalable, reproducible and compatible with pharmaceutical responsibility.

Making advanced therapies manufacturable

ATMPs and CAR-T therapies do not need another promise. They need a manufacturing model capable of carrying their biological complexity without reproducing the fragility of manual production.

The scientific path has been opened. The industrial path must now be governed.

This is where Fedegari’s role becomes strategic: integrating advanced robotic technologies within an aseptic architecture, closing the contamination-risk loop through automated sterilization and decontamination, and supporting the GMP-compliant manufacturing of the systems themselves.

Because in advanced therapies, the future does not depend only on what can be discovered. It depends on what can be produced, protected and delivered with confidence.

When manufacturing becomes ready, breakthrough can move closer to the patient.

 

 

Continue the conversation